Candidemia in cancer patients: A prospective, multicenter surveillance study by the invasive fungal infection group (IFIG) of the European organization for research and treatment of cancer (EORTC)

C. Girmenia, A. Marinus, L. Collette, C. Doyen, F. Meunier, Pietro Martino, Bernadette Lebeau, Vladimir Kremery, David Spence, Bernard Vandercam, Raoul Herbrecht, Jacques Troncy, Michel Aoun, Damir Nemet, Maria Anna Viviani, Claudio Viscoli, Alain Cometta, Robert Hemmer, Catherine Cordonnier, John CohenAntoine Thyss, Dan Engelhard, Christophe Hennequin, Simon De Marie, Mareva Giacchino, Per Ljungmen, Dirk Sehrijvers, Ben De Pauw, Philippe Moreau, Giuseppe Todeschini, Fritz Offner, Michèle Tjean, Anna Gregor, Raffaella Giacchino

Research output: Contribution to journalArticlepeer-review

Abstract

In a surveillance study of candidemia in cancer patients that was conducted by the European Organization for Research and Treatment of Cancer, 249 episodes were noted; Candida albicans was isolated in 70% (63) of the 90 cases involving patients with solid tumors (tumor patients) and in 36% (58) of the 159 involving those with hematologic disease (hematology patients). Neutropenia in tumor patients and acute leukemia and antifungal prophylaxis in hematology patients were significantly associated with non-albicans candidemia in a multivariate analysis. Overall 30-day mortality was 39% (97 of 249). In a univariate analysis, Candida glabrata was associated with the highest mortality rate (odds ratio, 2.66). Two multivariate analyses showed that mortality was associated with older age and severity of the underlying disease. Among hematology patients, additional factors associated with mortality were allogeneic bone marrow transplantation, septic shock, and lack of antifungal prophylaxis.

Original languageEnglish
Pages (from-to)1071-1079
Number of pages9
JournalClinical Infectious Diseases
Volume28
Issue number5
Publication statusPublished - 1999

ASJC Scopus subject areas

  • Immunology

Fingerprint Dive into the research topics of 'Candidemia in cancer patients: A prospective, multicenter surveillance study by the invasive fungal infection group (IFIG) of the European organization for research and treatment of cancer (EORTC)'. Together they form a unique fingerprint.

Cite this